An increasing number of skeletal myopathies are demonstrating favorable responses to alterations of the TGFβ signaling pathway. However, future research is needed to fully understand the downstream molecular signature associated with this pathway in order to develop more specific targeted therapies.
No takes yet. Share an insight, caveat, or question.
MacDonald et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: